Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR2 | O60603 | 4/20 | 0.59 |
| ▸ | GLP1R | P43220 | 1/20 | 0.56 |
| ▸ | GCGR | P47871 | 1/20 | 0.56 |
| ▸ | GIPR | P48546 | 1/20 | 0.56 |
| ▸ | KISS1R | Q969F8 | 6/20 | 0.56 |
| ▸ | IL23R | Q5VWK5 | 5/20 | 0.56 |
| ▸ | MAGI3 | Q5TCQ9 | 1/20 | 0.52 |
| ▸ | NPY2R | P49146 | 2/20 | 0.52 |
| ▸ | GHSR | Q92847 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29390396 | 0.92 | MAGI3 (0.55) | TLR2KISS1RIL23RMAGI3 | |
| SCHEMBL29608081 | 0.91 | GLP1R (0.62) | TLR2GLP1RGCGRGIPRKISS1R | |
| SCHEMBL29436295 | 0.91 | KISS1R (0.56) | TLR2GLP1RGCGRGIPRKISS1R | |
| SCHEMBL31597621 | 0.89 | ERAP2 (0.56) | TLR2KISS1RIL23RMAGI3GHSR | |
| SCHEMBL30601285 | 0.89 | GLP1R (0.64) | TLR2GLP1RGCGRGIPRKISS1R | |
| SCHEMBL30262080 | 0.89 | TLR2 (0.59) | TLR2GLP1RGCGRGIPRMAGI3 | |
| SCHEMBL30512677 | 0.87 | MAGI3 (0.62) | TLR2GLP1RGCGRGIPRIL23R | |
| SCHEMBL30608430 | 0.87 | ERAP2 (0.58) | TLR2KISS1RIL23RMAGI3GHSR | |
| SCHEMBL29609550 | 0.87 | ERAP2 (0.60) | TLR2KISS1RIL23RMAGI3NPY2R | |
| SCHEMBL31694490 | 0.87 | IL23R (0.57) | TLR2GLP1RGCGRGIPRKISS1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11713344-B2 | Acylated oxyntomodulin peptide analog | DONG-A ST CO., LTD. (KR) | 2023-08-01 | — | — | US | disclosed |
| US-20220119473-A1 | ACYLATED OXYNTOMODULIN PEPTIDE ANALOG | DONG-A ST CO., LTD. (KR) | 2022-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11713344-B2 | Acylated oxyntomodulin peptide analog | GLP1R, GIPR, GPR119 | TLR2 1131/4885GLP1R 1/4885GCGR 5/4885 |
| US-20220119473-A1 | ACYLATED OXYNTOMODULIN PEPTIDE ANALOG | GLP1R, GIPR, GPR119 | TLR2 1131/4885GLP1R 1/4885GCGR 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.